...Biotechnology Co. Ltd. Applied Molecular Transport Inc Pliant Therapeutics Inc. Ayala Pharmaceuticals Inc. Lyra Therapeutics Inc. ORIC Pharmaceuticals Inc. Keros Therapeutics Inc. Zentalis Pharmaceuticals Inc. Imara...

...stem cell transplantation. FDA granted the combination Priority Review in March. Zentalis launches Shanghai-based JV Zentalis Pharmaceuticals Inc....
...of motor neuron 2 centromeric Robin Sawka, BioCentury Staff Kadmon Holdings Inc. Sorrento Therapeutics Inc. Novartis AG AveXis Inc. Incyte Corp. MorphoSys AG Zentalis Pharmaceuticals Inc. Bruton's...

...#), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) filgotinib (GLPG0634, GS-6034) Sarasar, lonafarnib (mk-6336, sch 066336) SRF617 Keytruda, pembrolizumab (MK-3475, lambrolizumab) Zentalis Pharmaceuticals Inc. Gilead...

...precipitously. A handful of companies managed to list during that period: Keros Therapeutics Inc. (NASDAQ:KROS), Zentalis Pharmaceuticals Inc....

...first-day gains, and all three -- ORIC Pharmaceuticals Inc. (NASDAQ:ORIC), Keros Therapeutics Inc. (NASDAQ:KROS) and Zentalis Pharmaceuticals Inc....

...least 26%, and all three -- ORIC Pharmaceuticals Inc. (NASDAQ:ORIC), Keros Therapeutics Inc. (NASDAQ:KROS) and Zentalis Pharmaceuticals Inc....

...least 26%, and all three -- ORIC Pharmaceuticals Inc. (NASDAQ:ORIC), Keros Therapeutics Inc. (NASDAQ:KROS) and Zentalis Pharmaceuticals Inc....

...above expectations. With its market debut on Friday, ORIC joins Keros Therapeutics Inc. (NASDAQ:KROS) and Zentalis Pharmaceuticals Inc....

...since the spread of COVID-19 began to upend the markets in late February. Last week, Zentalis Pharmaceuticals Inc....

...receptive to new biopharma listings, even amid weeks of uncertainty due to the COVID-19 outbreak. Zentalis Pharmaceuticals Inc....
...IPO price (see “Cratering Market Spoils Debut” ; “Passage Prices Upsized IPO” ). Paul Bonanos, Associate Editor Zentalis Pharmaceuticals Inc. IPO...